Innovative Chronic Pain Treatment expand IP Protection in China’s US$163 Billion Pharmaceutical Market Herzliya, Israel and Calgary, Alberta - April 07, 2025 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that a divisional application for its Chinese (CN) liposome-based CBD technology patent was filed. Following the recently granted patent in India for a prolonged-release pharmaceutical formulation using liposomes to encapsulate CBD, Innocan is actively advancing ...
[ more ]
